CDNA encoding a human ATP synthase Fo subunit (ASYSD)
    1.
    发明授权
    CDNA encoding a human ATP synthase Fo subunit (ASYSD) 失效
    CDNA编码人类ATP合成酶Fo亚基(ASYSD)

    公开(公告)号:US5763248A

    公开(公告)日:1998-06-09

    申请号:US948195

    申请日:1997-10-09

    CPC分类号: C12N9/14 A61K38/00

    摘要: The present invention provides a human ATP synthase d subunit (ASYSD) and polynucleotides which encode ASYSD. The invention also provides expression vectors, host cells, agonists, antisense molecules, antibodies, or antagonists. The invention also provides methods for producing ASYSD and for treating disorders associated with expression of ASYSD.

    摘要翻译: 本发明提供了人ATP合成酶d亚基(ASYSD)和编码ASYSD的多核苷酸。 本发明还提供表达载体,宿主细胞,激动剂,反义分子,抗体或拮抗剂。 本发明还提供了用于产生ASYSD和用于治疗与ASYSD表达相关的疾病的方法。

    Cell growth-controlling oligonucleotides
    3.
    发明授权
    Cell growth-controlling oligonucleotides 失效
    细胞生长控制寡核苷酸

    公开(公告)号:US6124091A

    公开(公告)日:2000-09-26

    申请号:US867230

    申请日:1997-05-30

    摘要: The present invention provides a partial cDNA corresponding to an RNA containing double stranded regions (R-RNA), which, when transcribed in vitro, gives rise to an RNA transcript that activates PKR. An approximately 226-252 bp nucleotide (nt) sequence responsible for activation of PKR (the activation sequence) has been identified within the cDNA and isolated. Antisense oligonucleotides corresponding to specific portions of the 252 nt cDNA fragment stimulate proliferation of different cells in culture. Various portions of the cDNA or R-RNA may also be used to inhibit cell proliferation in cell cultures.The present invention further provides pharmaceutical compositions comprising the subject nucleic acid fragments and oligonucleotides. Kits which comprise at least one of the subject isolated nucleic acid molecules or oligonucleotides and a pharmaceutically acceptable carrier are also provided.

    摘要翻译: 本发明提供了对应于含有双链区域(RNA-RNA)的RNA的部分cDNA,其在体外转录时产生激活PKR的RNA转录物。 已经在cDNA内鉴定了负责激活PKR(活化序列)的约226-252bp的核苷酸(nt)序列并分离。 对应于252nt cDNA片段的特定部分的反义寡核苷酸刺激培养物中不同细胞的增殖。 cDNA或R-RNA的各种部分也可用于抑制细胞培养物中的细胞增殖。 本发明进一步提供包含本发明核酸片段和寡核苷酸的药物组合物。 还提供了包含受试者分离的核酸分子或寡核苷酸中的至少一个的药盒和药学上可接受的载体。

    Synthetic eukaryotic promoters containing two inducible elements
    4.
    发明授权
    Synthetic eukaryotic promoters containing two inducible elements 失效
    含有两种可诱导元件的合成真核启动子

    公开(公告)号:US5877018A

    公开(公告)日:1999-03-02

    申请号:US633289

    申请日:1996-04-16

    摘要: Synthetic inducible eukaryotic promoters for the regulation of transcription of a gene achieve improved levels of protein expression and lower basal levels of gene expression. Such promoters contain at least two different classes of inducible elements, usually by modification of a native promoter containing one of the inducible elements by inserting the other of the inducible elements. In embodiments, additional metal responsive elements IR:Es) and/or glucocorticoid responsive elements (GREs) are provided to native promoters, particularly the hMT-IIA and MMTV-LTR promoters. One or more constitutive elements may be functionally disabled to provide the lower basal levels of gene expression.

    摘要翻译: 用于调节基因转录的合成诱导型真核启动子实现了蛋白质表达水平的提高和基因表达水平的降低。 这样的启动子含有至少两种不同类型的可诱导元件,通常通过插入另外一种可诱导元件修饰含有可诱导元件之一的天然启动子。 在实施方案中,向天然启动子,特别是hMT-IIA和MMTV-LTR启动子提供额外的金属响应元件IR:Es)和/或糖皮质激素反应元件(GRE)。 一个或多个组成元件可以在功能上被禁用以提供较低的基础水平的基因表达。

    Phosphorothioate oligonucleotides that bind to the V3-loop and uses
thereof
    5.
    发明授权
    Phosphorothioate oligonucleotides that bind to the V3-loop and uses thereof 失效
    结合V3环的硫代磷酸寡核苷酸及其用途

    公开(公告)号:US5756710A

    公开(公告)日:1998-05-26

    申请号:US658616

    申请日:1996-06-05

    摘要: The present invention provides phosphorothioate oligonucleotide moieties comprising a phosphorothioate oligonucleotide comprising the sequence G.sub.m X.sub.n G.sub.p, wherein G is guanosine; X is thymidine, adenosine or cytidine, or a combination thereof; each of m, n and p is independently an integer greater than 2; the phosphorothioate oligonucleotide moiety being capable of binding to a V3 loop of HIV envelope glycoprotein. The invention further provides for a method of inhibiting HIV activity. The invention also provides for a method of inhibiting HIV activity in a subject. The invention further provides for a method of treating an HIV related disorder in a subject. Finally, the invention provides a pharmaceutical composition comprising a phosphorothioate oligonucleotide moiety and a pharmaceutically acceptable carrier.

    摘要翻译: 本发明提供硫代磷酸酯寡核苷酸部分,其含有包含序列GmXnGp的硫代磷酸酯寡核苷酸,其中G是鸟苷; X是胸苷,腺苷或胞苷,或其组合; m,n和p各自独立地为大于2的整数; 硫代磷酸酯寡核苷酸部分能够结合HIV包膜糖蛋白的V3环。 本发明进一步提供了抑制HIV活性的方法。 本发明还提供了抑制受试者中的HIV活性的方法。 本发明还提供了治疗受试者中HIV相关病症的方法。 最后,本发明提供包含硫代磷酸酯寡核苷酸部分和药学上可接受的载体的药物组合物。